Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xudong Ni
Observed names:
Ni, Xudong,
XuDong Ni
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
Observed institutions:
Mount Sinai Hospital,
University Health Network,
Shanghai Medical College of Fudan University,
University of Toronto,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
show all 7
ORCID:
0009-0005-3131-8964
Observed ORCID:
0009-0005-3131-8964
OpenAlex ID:
A5067093490
From biology to the clinic — exploring liver metastasis in prostate cancer
2024
·
Xudong Ni
, Yu Wei
, et al.
·
Nature Reviews Urology
·
25
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study
2024
·
Jian Pan
, Tingwei Zhang
, et al.
·
Therapeutic Advances in Medical Oncology
·
18
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
2022
·
Jian Pan
, Jinou Zhao
, et al.
·
Molecular Oncology
·
15
PDF
Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer
2023
·
Xudong Ni
, Luu Michael
, et al.
·
Journal of the National Comprehensive Cancer Network
·
13
PDF
Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response
2023
·
Jian Pan
, Jinou Zhao
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
11
Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients: a tumor marker prognostic study
2025
·
Xudong Ni
, Ziyun Wang
, et al.
·
International Journal of Surgery
·
10
Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer
2023
·
Xudong Ni
, Junlong Wu
, et al.
·
European Urology Oncology
·
5
Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy
2024
·
Beihe Wang
, Jian Pan
, et al.
·
BMC Cancer
·
4
Dual regulation of CXCR6 + CD8 + T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression
2026
·
Zhang Xingming
, Jianhua Wang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases
2025
·
Jian Pan
, Bin Zhu
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
3
Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS
2025
·
Xudong Ni
, Jixinnan Sui
, et al.
·
The Journal of Urology
·
2
The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials.
2023
·
Xudong Ni
, Yu Wei
, et al.
·
Journal of Clinical Oncology
·
2
Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone‐sensitive prostate cancer: the ARASENS and LATITUDE trials
2026
·
Xiyue Xiao
, Xudong Ni
, et al.
·
British Journal of Urology
PDF
Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy
2026
·
Xudong Ni
, Yufan Zhao
, et al.
·
Med
Integrating China’s Oncology Innovations into the Global Landscape: A Strategic Blueprint for Precision, Partnership, and Purpose
2026
·
Xudong Ni
, Tingwei Zhang
, et al.
·
Cancer Discovery
Evolving therapies, persistent gaps: a real-world look at survival trends in metastatic prostate cancer
2026
·
Yufan Zhao
, Xudong Ni
, et al.
·
Prostate Cancer and Prostatic Diseases
PDF
Authors’ Reply to the Letter to the Editor by Nguyen et al
2023
·
Xudong Ni
, Yao Zhu
·
Journal of the National Comprehensive Cancer Network
PDF
Pd21-07 Racial Impact (asian Vs. White) on the Prognosis of Patients With De Novo Mcspc: an Analysis on Latitude, Seer and Ncdb
2023
·
XuDong Ni
, Michael Luu
, et al.
·
The Journal of Urology
PDF
Racial impact (Asian vs. White) on the prognosis of patients with de novo mCSPC: An analysis on LATITUDE, SEER and NCDB.
2023
·
Xudong Ni
, Michael Luu
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
22
Citation count:
111
H-index:
6
I10-index:
6
Year
Topic
Type